Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700)

Katsuyoshi Hori

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Despite extensive research efforts, effective therapies for refractive cancers have not yet been established, and development of successful treatment strategies remains the most important task in the field of oncology. We recently showed that AVE8062 (formerly AC7700), a derivative of combretastatin A-4, achieved irreversible stasis of tumor blood flow (TBF), thereby causing necrosis of tumor tissue by halting the supply of nutrients. Such effects were unrelated to cancertype. In this review, we summarize our experiments on antivascular and antitumor effects by AVE8062. We maintain that such starvation tactics against solid tumors constitute a new therapeutic strategy for all solid tumors, including refractory cancers.

Original languageEnglish
Pages (from-to)357-360
Number of pages4
JournalChemotherapy
Volume51
Issue number6
DOIs
Publication statusPublished - 2005 Oct 1

Keywords

  • AVE8062
  • Combretastatin A-4
  • Tumor blood flow

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700)'. Together they form a unique fingerprint.

Cite this